Global Cord Blood Corp

Healthcare US CORBF

1.05USD
-0.2(16.00%)

Last update at 2025-06-12T15:52:00Z

Day Range

1.051.05
LowHigh

52 Week Range

0.023.00
LowHigh

Fundamentals

  • Previous Close 1.25
  • Market Cap174.09M
  • Volume140000
  • P/E Ratio2.09
  • Dividend Yield1.40%
  • EBITDA656.79M
  • Revenue TTM1243.26M
  • Revenue Per Share TTM10.23
  • Gross Profit TTM 1059.95M
  • Diluted EPS TTM0.58

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-03-31 2021-03-31 2020-03-31 2019-03-31 2018-03-31
Type yearly yearly yearly yearly yearly
Date 2022-03-31 2021-03-31 2020-03-31 2019-03-31 2018-03-31
Income before tax 627.84M 610.75M 578.81M 356.46M 303.54M
Minority interest -8.41800M 6.59M 6.36M 5.43M 5.39M
Net income 501.06M 508.25M 470.72M 291.12M 237.10M
Selling general administrative 187.06M 174.36M 190.23M 169.32M 243.50M
Selling and marketing expenses 241.72M 237.69M 261.96M 235.06M 219.20M
Gross profit 1059.95M 980.69M 1032.33M 800.73M 755.28M
Reconciled depreciation 47.92M 49.09M 49.45M 52.37M 50.59M
Ebit 608.87M 544.87M 559.03M 352.38M 303.01M
Ebitda 628.78M 518.05M 572.00M 404.75M 353.60M
Depreciation and amortization 19.91M -26.82100M 12.97M 52.37M 50.59M
Non operating income net other - - - 0.00000M 0.00000M
Operating income 608.87M 544.87M 559.03M 381.66M 279.86M
Other operating expenses 634.39M 614.77M 662.43M 605.10M 656.90M
Interest expense 38.56M 133.83M 49.25M 0.00000M 3.26M
Tax provision 118.35M 94.55M 101.08M 61.26M 62.66M
Interest income 32.61M 30.90M 12.39M 30.89M 19.45M
Net interest income 32.61M 30.90M 25.36M 25.32M 18.68M
Extraordinary items - - - 0.00000M 0.00000M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense 118.35M 94.55M 101.08M 61.26M 62.66M
Total revenue 1243.26M 1159.64M 1221.46M 986.75M 936.77M
Total operating expenses 451.08M 435.82M 473.30M 419.07M 475.42M
Cost of revenue 183.31M 178.95M 189.13M 186.03M 181.48M
Total other income expense net 18.97M 65.88M 19.78M -50.51600M 4.99M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops 509.48M 516.21M 477.73M 295.20M 240.88M
Net income applicable to common shares 501.06M 508.25M 470.72M 291.12M 237.10M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2022-03-31 2021-03-31 2020-03-31 2019-03-31 2018-03-31
Type yearly yearly yearly yearly yearly
Date 2022-03-31 2021-03-31 2020-03-31 2019-03-31 2018-03-31
Total assets 8534.52M 7906.33M 7219.85M 6550.95M 5844.44M
Intangible assets 83.58M 88.20M 92.82M 97.44M 102.06M
Earning assets - - - - -
Other current assets 11.94M 47.79M 44.78M 14.75M 13.06M
Total liab 3649.55M 3517.88M 3331.36M 3128.19M 2725.69M
Total stockholder equity 4879.32M 4381.86M 3882.13M 3417.34M 3113.35M
Deferred long term liab - - - 0.00000M 0.00000M
Other current liab 179.82M 331.99M 292.64M 100.09M 90.43M
Common stock 0.08M 0.08M 0.08M 0.08M 0.08M
Capital stock 0.08M 0.08M 0.08M 0.08M -
Retained earnings 2887.25M 2386.19M 1877.94M 1407.22M 1116.87M
Other liab 3002.99M 2891.26M 2758.80M 2532.55M 2257.52M
Good will - - - 0.00000M 0.00000M
Other assets 756.95M 709.25M 643.20M 463.75M 437.98M
Cash 6660.98M 6075.80M 5473.37M 4997.86M 4250.61M
Cash and equivalents 6660.98M 6075.80M 5473.37M 4997.86M 4250.61M
Total current liabilities 646.56M 626.47M 570.78M 595.64M 468.18M
Current deferred revenue 458.26M 449.36M 402.75M 461.99M 366.37M
Net debt -6660.83700M -6074.01500M -5469.87400M -4997.86100M -4250.61000M
Short term debt 0.15M 1.64M 1.72M 0.00000M 0.00000M
Short long term debt - - - 0.00000M 0.00000M
Short long term debt total 0.15M 1.78M 3.50M 0.00000M 0.00000M
Other stockholder equity 2098.77M 2098.77M 2098.77M 2098.77M 2051.05M
Property plant equipment 476.69M 503.69M 527.23M 545.34M 552.96M
Total current assets 6935.00M 6298.14M 5666.17M 5147.93M 4408.42M
Long term investments 282.30M 307.04M 290.44M 296.49M 343.01M
Net tangible assets 4795.73M 4293.66M 3789.30M 3319.89M 3011.29M
Short term investments - - - 0.00000M 0.00000M
Net receivables 161.30M 130.30M 104.25M 107.71M 117.03M
Long term debt - - - 0.00000M 0.00000M
Inventory 45.88M 44.26M 43.76M 27.61M 27.72M
Accounts payable 8.33M 9.48M 19.99M 33.57M 11.37M
Total permanent equity - - - 0.00000M 0.00000M
Noncontrolling interest in consolidated entity - - - 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests - - - 0.00000M 0.00000M
Accumulated other comprehensive income -106.78600M -103.17900M -94.66300M -88.73800M -54.65400M
Additional paid in capital - - - 0.00000M 0.00000M
Common stock total equity - 0.08M 0.08M 0.08M 0.08M
Preferred stock total equity - - - 0.00000M 0.00000M
Retained earnings total equity - - - 0.00000M 0.00000M
Treasury stock - -2.81500M -2.81500M -2.81500M -2.81500M
Accumulated amortization - - - 0.00000M 0.00000M
Non currrent assets other 696.19M 653.41M 592.50M 418.77M 406.68M
Deferred long term asset charges - - - 0.00000M 0.00000M
Non current assets total 1599.52M 1608.19M 1553.69M 1403.03M 1436.01M
Capital lease obligations 0.15M 1.78M 3.50M 0.00000M 0.00000M
Long term debt total 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2022-03-31 2021-03-31 2020-03-31 2019-03-31 2018-03-31
Type yearly yearly yearly yearly yearly
Date 2022-03-31 2021-03-31 2020-03-31 2019-03-31 2018-03-31
Investments -19.63500M -20.10700M -146.06100M -30.21000M -66.47700M
Change to liabilities 88.40M 139.24M 108.51M 352.24M 347.43M
Total cashflows from investing activities -19.63500M -20.10700M -146.06100M -30.21000M -66.47700M
Net borrowings - - - 0.00000M 0.00000M
Total cash from financing activities -7.72900M -6.07400M -4.03900M -21.19200M -2.01500M
Change to operating activities 14.49M 49.14M 54.31M 44.21M 60.11M
Net income 509.48M 516.21M 477.73M 295.20M 240.88M
Change in cash 585.19M 602.42M 475.51M 747.25M 740.35M
Begin period cash flow 6075.80M 5473.37M 4997.86M 4250.61M 3510.26M
End period cash flow 6660.98M 6075.80M 5473.37M 4997.86M 4250.61M
Total cash from operating activities 613.61M 630.71M 624.00M 792.12M 818.76M
Issuance of capital stock - - - - -
Depreciation 47.92M 49.09M 49.45M 52.37M 50.59M
Other cashflows from investing activities 0.15M 0.79M -123.01600M -123.01600M -123.01600M
Dividends paid - 0.00000M 0.00000M 18.17M 0.00000M
Change to inventory -5.33900M -6.83600M -24.06100M -5.33000M 0.29M
Change to account receivables -102.93300M -120.43600M -86.89700M -30.36700M 6.34M
Sale purchase of stock - - - 0.00000M 0.00000M
Other cashflows from financing activities -7.72900M -6.07400M -4.03900M -3.01900M -2.01500M
Change to netincome 68.39M 15.04M 39.76M 85.18M 110.19M
Capital expenditures 19.79M 20.89M 24.24M 30.69M 67.07M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital -3.76900M 58.33M 64.08M 363.45M 420.19M
Stock based compensation - 11.69M 37.62M 0.00000M 84.27M
Other non cash items 56.74M 14.24M 39.95M 95.79M 32.77M
Free cash flow 593.82M 609.82M 599.76M 761.43M 751.70M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CORBF
Global Cord Blood Corp
-0.2 16.00% 1.05 2.09 - 0.16 0.29 -1.1271
TMO
Thermo Fisher Scientific Inc
0.56 0.14% 415.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
0.15 0.08% 204.88 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc
-0.61 0.51% 119.11 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc
2.75 0.52% 526.93 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

Profile

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Global Cord Blood Corp

Bank of China Tower, Central, Hong Kong

Key Executives

Name Title Year Born
Ms. Ting Zheng CEO & CEO of Beijing Division 1972
Mr. Bing Chuen Chen Chief Financial Officer 1976
Ms. Xin Xu Chief Technology Officer 1954
Ms. Rui Arashiyama Chief Exec. Officer of Guangdong & Zhejiang Divisions 1959
Ms. Cathy Bai VP of Corp. Fin. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.